Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506143 | 0.86 | GPR119 (1.00) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL12506129 | 0.83 | GPR119 (1.00) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL12505970 | 0.82 | GPR119 (1.00) | GPR119CYP3A4CYP2C19CNR1CNR2 | |
| SCHEMBL12506069 | 0.77 | GPR119 (0.79) | GPR119CYP3A4CYP2C19CNR2 | |
| SCHEMBL12506123 | 0.76 | GPR119 (0.94) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL12506097 | 0.74 | GPR119 (1.00) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL15312685 | 0.74 | GPR119 (0.77) | GPR119CYP3A4CYP2C19CNR2 | |
| SCHEMBL12506070 | 0.74 | GPR119 (0.79) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL15315324 | 0.74 | GPR119 (0.78) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL12506049 | 0.74 | GPR119 (0.86) | GPR119CYP3A4CYP2C19CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM. CO., LTD (KR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR3 | GPR119 1/4885CYP3A4 3885/4885CYP2C19 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.